Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA nanobody CAR-T in relapsed/refractory myeloma
NCT03664661Phase 1Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2018
- Primary completion
- Apr 2019
- Modality
- CAR-T Cells, Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA nanobody CAR-T cells in multiple myeloma (MM), sponsored by Henan Cancer Hospital. Primary endpoint: occurrence of study related adverse events at 4 weeks. Status: unknown.
02
Drugs
BCMA nanobody CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03664661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664661.